Infections during low-dose methotrexate treatmentin rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 24, Issue 6, 1995, Pages 411-421

  Boerbooms, Agnes M Th ^a   Kerstens, Pit J S M ^a   van Loenhout, Jos W A ^a   Mulder, Jan ^b   van de Putte, Leo B A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

infections; methotrexate; psoriasis (arthropathy); Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; GOLD; METHOTREXATE; PREDNISONE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; MALE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; URINARY TRACT INFECTION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; MALE; METHOTREXATE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; PSORIASIS;

EID: 0029016757     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(95)80009-3     Document Type: Article

References (86)

1. Low-dose pulse methotrexate therapy in rheumatoid arthritis
2. Methotrexate in the treatment of rheumatoid arthritis
3. Low-dose methotrexate in rheumatoid arthritis
4. Low-dose methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature
5. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis
6. Low-dose methotrexate in rheumatoid arthritis. Long term observations
7. Efficacy of low-dose methotrexate in rheumatoid arthritis
8. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized double-blind study
9. Methotrexate in rheumatoid arthritis
10. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four-week controlled trial
11. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
12. Toxicity to methotrexate in rheumatoid arthritis
13. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three-months
14. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
15. Methotrexate in refractory rheumatoid arthritis
16. Long-term methotrexate in refractory rheumatoid arthritis, concurrent use of prednisone possible improves drug survival
17. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis A case control study of 131 patients
18. Methotrexate in rheumatoid arthritis. Toxic effects as the Major factor in limiting long-term treatment
19. Prospective long-term follow-up of methotrexate therapy in rheumatoid arthritis; toxicity, efficacy and radiological progression
20. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
21. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study
22. Low-dose methotrexate compared with auronofin in adult rheumatoid arthritis: a thirty-six-week, double-blind trial
23. Adverse experience with methotrexate during 176 week of a long term prospective trial in patients with rheumatoid arthritis
24. The efficacy and toxicity of a constant low-dose of methotrexate as a treatment for intractable rheumatoid arthritis
25. Long-term methotrexate therapy for rheumatoid arthritis
26. Analysis of methotrexate treatment effect in a longitudinal observational study: Utility of cluster analysis
27. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis A forty-eight-week randomized double blind trial
28. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis
29. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-months update
30. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months
31. Comparison of azathioprine methotrexate and the combination of both in the treatment of rheumatoid arthritis A controlled clinical trial
32. Methotrexate therapy in rheumatoids arthritis: A life table review of 587 patients treated in community practise
33. Infection rate of use of antibiotica in patients with rheumatoid arthritis treated with methotrexate
34. Low-dose Methotrexate in rheumatic diseases, efficacy, side effects and risk factors for side effects
35. Methotrexate maintenance therapy and liver damage in psoriasis
36. Methotrexate for psoriasis
37. Psoriasis
38. Pneumocystis carinii pneumonia following therapy for rheumatoid arthritis
39. Cryptocococcus associated with low-dose methotretrate for arthritis
40. Nocardiasis associated with low-dose methotrexate for rheumatoid arthritis
41. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate
42. Rheumatoid Arthritis, Methotrexate therapy, and pneumocystis pneumonia
43. Complications of immunosuppression associated with weekly low-dose methotrexate
44. Pneumocystis carinii pneumonia complicating low-dose methotrexate treatment for rheumatoid arthritis
45. Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis
46. Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low-dose methotrexate and prednisone
47. Pneumocystis carinii infection complicating cytotoxic therapy in two patients with lymphopenia, but a normal white cell count
48. Pneumocystis carinii associated with low-dose methotrexate treatment for rheumatoid arthritis
49. Pulmonary cryptococcosis mimicking methotrexate pneumonitis
50. Should methotrexate be discontinued before elective orthpaedic surgery in patients with rheumatoid arthritis?
51. Methotrexate (MTX) and postoperative joint infections in rheumatoid arthritis (RA) patients undergoing total joint arthroplasty (TJA)
52. Local infections complicating large joint replacement in rheumatoid arthritis treated with methotrexate versus not treated with methotrexate
53. Reconsideration of the risk of postarthroplasty infection in patients treated with methotrexate
54. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis
55. Diagnostic criteria for rheumatoid arthritis 1985 revision
56. Urinary tract infection in patients with rheumatoid arthritis
57. Pneumaocystis carinii pneumonia following cyclosporine A and methotrexate treated rheumatoid arthritis
58. An asteroides infection complicating rheumatoid arthritis
59. Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis
60. Complications during methotrexate therapy for psoriasis
61. Psoriasis, methotrexate and tuberculosis
62. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy
63. Herpes simplex hepatitis in a patient with psoriatic arthritis taking prednisone and methotrexate. Report and review of the literature
64. Mechanism of glucocorticosteroid action in immune processes
65. Risk of infections complications in patients taking glucoticosteroids
66. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis
67. Frequency of infections among rheumatoid arthritis patients, before and after disease onset
68. Frequency of infections among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism
69. Infection in rheumatoid arthritis
70. Rheumatoid arthritis and mortality
71. Survival and death in rheumatoid arthritis
72. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis
73. Response of immunoregulatory lymphocyte subsets to methotrexate in rheumatoid arthritis
74. Methotrexate may affect certain T lymphocyte subsets in rheumatoid arthritis resulting in susceptibility to pneumocystis carinii infection
75. Methotrexate mechanisms of action in rheumatoid arthritis
76. Methotrexate: anti-inflammatory or immunosuppressive?
77. Circulating soluble necrosis factor and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine
78. Inhibition of neutrophil chemotaxis in methotrexate treated rheumatoid arthritis patients
79. Controlled trial of cyclophosphamide in rheumatoid arthritis
80. Controlled trial of cyclophosphamide in rheumatoid arthritis
81. Infectious complications of cyclophosphamide treatment for vasculitis
82. Measures of immunologic and inflammatory responses in vitro in rheumatoid arthritis patients treated with methotrexate
83. Effect of low-dose methotrexate on neutrophil chemotaxis induced by leukotriene B4 and complement C 5a
84. Studies on the effect of methotrexate on macrophage
85. The effects of methotrexate on the production of activity of interleukin-1